Abstract:The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest over the last decades. In particular, the analysis of biomarkers in cancer patients within the pre- and post-therapeutic period is required to identify several types of cells, which carry a risk for a disease progression and subsequent post-therapeutic relapse. Cancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. At the time point of tumor initiation, CSCs originate from either differentiated cells or adult tissue resident stem cells. Due to their importance, several biomarkers that characterize CSCs have been identified and correlated to diagnosis, therapy and prognosis. However, CSCs have been shown to display a high plasticity, which changes their phenotypic and functional appearance. Such changes are induced by chemo- and radiotherapeutics as well as senescent tumor cells, which cause alterations in the tumor microenvironment. Induction of senescence causes tumor shrinkage by modulating an anti-tumorigenic environment in which tumor cells undergo growth arrest and immune cells are attracted. Besides these positive effects after therapy, senescence can also have negative effects displayed post-therapeutically. These unfavorable effects can directly promote cancer stemness by increasing CSC plasticity phenotypes, by activating stemness pathways in non-CSCs, as well as by promoting senescence escape and subsequent activation of stemness pathways. At the end, all these effects can lead to tumor relapse and metastasis. This review provides an overview of the most frequently used CSC markers and their implementation as biomarkers by focussing on deadliest solid (lung, stomach, liver, breast and colorectal cancers) and hematological (acute myeloid leukemia, chronic myeloid leukemia) cancers. Furthermore, it gives examples on how the CSC markers might be influenced by therapeutics, such as chemo- and radiotherapy, and the tumor microenvironment. It points out, that it is crucial to identify and monitor residual CSCs, senescent tumor cells, and the pro-tumorigenic senescence-associated secretory phenotype in a therapy follow-up using specific biomarkers. As a future perspective, a targeted immune-mediated strategy using chimeric antigen receptor based approaches for the removal of remaining chemotherapy-resistant cells as well as CSCs in a personalized therapeutic approach are discussed.

Biomarkers of Cancer Stem Cells for Experimental Research and Clinical Application

Biomarkers Of Head And Neck Cancer Stem Cells And Targeted Therapeutic Strategies

Monitoring Cancer Stem Cells: Insights into Clinical Oncology.

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

Biomarkers and targeted therapy for cancer stem cells

Advances in Biomarkers and Endogenous Regulation of Breast Cancer Stem Cells.

Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care

Molecular Imaging in Tracking Tumor Stem-Like Cells

Cancer Stem Cells: Constantly Evolving and Functionally Heterogeneous Therapeutic Targets.

Breast cancer stem cells as novel biomarkers

Clinical Implication of Cancer Stem Cells

Colorectal Cancer Stem Cell Biomarkers: Biological Traits and Prognostic Insights

Cancer Stem Cell Biomarkers in the Nervous System

Cancer Stem Cells A Review Of Potential Clinical Applications

Cancer Stem Cells, Metabolism, and Therapeutic Significance

Breast Cancer Stem Cells: Biomarkers, Identification and Isolation Methods, Regulating Mechanisms, Cellular Origin, and Beyond

Surface markers of cancer stem cells in solid tumors.

Cancer Stem Cell markers: Symphonic masters of chemoresistance and immune evasion

Cancer Stem Cells: Therapeutic Implications and Perspectives in Cancer Therapy

Cancer Stem Cell Markers for Liver Cancer and Pancreatic Cancer.

Advances in Treatments Targeting Tumor-Promoting Factors and Pathways